Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Arcutis Biotherapeutics Logo
Arcutis Biotherapeutics Growth Score
82
CB Rank
52744
Heat Score
56
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.
Founded
obfuscation
PublicPost-IPO Equity Westlake Village, California, United States251-500 arcutis.com
Biopharma
Biotechnology
Health Diagnostics
Pharmaceutical
Therapeutics
Overview

Arcutis Biotherapeutics
Total Funding
obfuscation
Growth Score
82
Heat Score
56

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score82
-12 pts
in past quarter
Heat Score 56
-11 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Arcutis Biotherapeutics

CB Rank
52744
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.
Founded
obfuscation
PublicPost-IPO Equity Westlake Village, California, United States251-500 arcutis.com
Biopharma
Biotechnology
Health Diagnostics
Pharmaceutical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Arcutis Biotherapeutics, Inc.
Operating Status Active
Stock Symbol  NASDAQ:ARQT
Company Type For Profit
Founders  Bhaskar Chaudhuri, David Osborne
About the Company
Arcutis Biotherapeutics is a privately held clinical-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company was founded in 2016 and is based in Westlake Village, California.
Phone Number 805-418-5006
Contact Email information@arcutis.com
Predictions & Insights

Growth Insight

See this Growth Insight
Arcutis Biotherapeutics is
Lorem
 to be growing
Top Contributing Factors
Financial Growth

Products & Services

ZORYVE Cream (roflumilast) 0.3%
A topical cream for treating plaque psoriasis in patients aged 6 years and older.
ZORYVE Foam (roflumilast) 0.3%
A topical foam formulation for treating seborrheic dermatitis in patients aged 9 years and older.

Research & Development

Arcutis Biotherapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Arcutis Biotherapeutics Logo
Post-IPO Equity - Arcutis Biotherapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Arcutis Biotherapeutics Logo
Post-IPO Equity - Arcutis Biotherapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Arcutis Biotherapeutics Logo
Post-IPO Equity - Arcutis Biotherapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Arcutis Biotherapeutics Logo
Post-IPO Equity - Arcutis Biotherapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Arcutis Biotherapeutics Logo
Post-IPO Equity - Arcutis Biotherapeutics
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Arcutis Biotherapeutics Logo
Post-IPO Equity - Arcutis Biotherapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Arcutis Biotherapeutics Logo
Post-IPO Equity - Arcutis Biotherapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Arcutis Biotherapeutics Logo
Post-IPO Equity - Arcutis Biotherapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Arcutis Biotherapeutics Logo
Post-IPO Equity - Arcutis Biotherapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Arcutis Biotherapeutics Logo
Post-IPO Equity - Arcutis Biotherapeutics
—
obfuscation
— Post-IPO Equity

Investors

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 251-500 Employee Profiles 14 Board Members and Advisors 6 Contacts 311

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 6, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 27, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 27, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 22, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

12,910
54.76%
 in past month

IT Spend

$5.7MThis year, Arcutis Biotherapeutics is projected to spend $5.7M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
TCL Logo
TCL
100
HP SureSupply Logo
HP SureSupply
100
Jabil (JBL) Logo
Jabil (JBL)
100

Active Website Tech Count

62Arcutis Biotherapeutics is actively using 62 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, SSL by Default, and  Viewport Meta.

Total IP

61The intellectual property of Arcutis Biotherapeutics includes 51 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Arcutis Biotherapeutics has registered 10 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Arcutis Biotherapeutics's headquarters? Arcutis Biotherapeutics is located in Westlake Village, California, United States.Who invested in Arcutis Biotherapeutics? Arcutis Biotherapeutics has 12 investors including SLR Capital Partners and  Frazier Healthcare Partners.When was the last funding round for Arcutis Biotherapeutics? Arcutis Biotherapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Arcutis Biotherapeutics's competitors? Alternatives and possible competitors to Arcutis Biotherapeutics may include LEO Pharma, Roivant Sciences, and  ImageneBio.How much funding has Arcutis Biotherapeutics raised to date? Arcutis Biotherapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(250d0b0 1)
|